BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/25/2023 8:26:32 AM | Browse: 185 | Download: 578
 |
Received |
|
2023-03-17 02:25 |
|
Peer-Review Started |
|
2023-03-17 02:28 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-06-19 07:16 |
|
Revised |
|
2023-07-02 15:10 |
|
Second Decision |
|
2023-08-01 02:31 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-08-01 07:54 |
|
Articles in Press |
|
2023-08-01 07:54 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-07-31 08:08 |
|
Typeset the Manuscript |
|
2023-08-16 01:28 |
|
Publish the Manuscript Online |
|
2023-08-25 08:26 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Case Control Study |
| Article Title |
Reduction rate of monoclonal protein as a useful prognostic factor in standard-risk group of newly diagnosed multiple myeloma Reduction rate of M protein as a useful prognostic factor in standard-risk group of newly diagnosed multiple myeloma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Min Liu and Jun-Yu Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jun-Yu Zhang, MM, Chief Doctor, Department of Hematology, Lishui Municipal Central Hospital, No. 289 Kuocang Road, Lishui 323000, Zhejiang Province, China. zhangjunyu815@163.com |
| Key Words |
Multiple myeloma; Monoclonal protein; Progression-free survival; Chemotherapy |
| Core Tip |
Multiple myeloma (MM) is a common hematologic malignancy that originates from a malignant clone of plasma cells. Solitary plasmacytoma, history of diabetes, and platelet count are considered as prognostic factors for MM. But some patients are still associated with much worse outcomes without any prognostic predictors. This study aimed to observe the reduction rate of monoclonal protein after the first and fourth chemotherapy cycles, which is considered as a new prognostic factor for progression-free survival in standard-risk group of newly diagnosed MM patients. |
| Publish Date |
2023-08-25 08:26 |
| Citation |
Liu M, Zhang JY. Reduction rate of monoclonal protein as a useful prognostic factor in standard-risk group of newly diagnosed multiple myeloma. World J Clin Cases 2023; 11(24): 5643-5652 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i24/5643.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i24.5643 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
